Immune checkpoint inhibitors (ICIs) have become a pillar of cancer therapy. The cardiovascular complications of ICIs extend beyond myocarditis and can involve any component of the cardiovascular system, including the pericardium, coronary arteries and conduction system. Clinicians caring for patients treated with ICIs must be vigilant for the cardiovascular complications of these therapies, which might portend a poor prognosis.
References
Haslam, A., Gill, J. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw. Open 3, e200423 (2020).
D’Souza, M. et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur. Heart J. 42, 1621–1631 (2021).
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755–1764 (2018).
Ball, S. et al. Cardiovascular toxicities of immune checkpoint inhibitors. J. Am. Coll. Cardiol. 74, 1714–1727 (2019).
Won, T. et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 41, 111611 (2022).
Gong, J. et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J. Immunother. Cancer 9, e002771 (2021).
Vuong, J. T. et al. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications. J. Am. Coll. Cardiol. 79, 577–593 (2022).
Drobni, Z. D. et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142, 2299–2311 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.G.N. has received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, CRO Oncology, Genentech, H3 Biomedicine, Roche and Sanofi, and has received grant funding from AstraZeneca and Bristol Myers Squibb for work related to the cardiovascular complications of immune checkpoint inhibitors. K.J. declares no competing interests.
Rights and permissions
About this article
Cite this article
Josan, K., Neilan, T.G. Immune checkpoint inhibitors: acute and chronic cardiovascular complications. Nat Rev Cardiol 20, 73–74 (2023). https://doi.org/10.1038/s41569-022-00827-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-022-00827-1
- Springer Nature Limited